Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.

Leighton X, Srikantan V, Pollard HB, Sukumar S, Srivastava M.

Cancer Lett. 2004 Jul 16;210(2):239-44.

PMID:
15183540
2.

Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.

Gonzalez R, Silva JM, Dominguez G, Garcia JM, Martinez G, Vargas J, Provencio M, España P, Bonilla F.

Br J Cancer. 1999 Oct;81(3):503-9.

3.

Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients.

Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G, Olsen C, Kallioniemi OP, Eidelman O, Pollard HB.

Clin Cancer Res. 2004 Apr 1;10(7):2344-50.

4.

Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.

Silva JM, Gonzalez R, Provencio M, Dominguez G, Garcia JM, Gallego I, Palacios J, España P, Bonilla F.

Breast Cancer Res Treat. 1999 Jan;53(1):9-17.

PMID:
10206068
5.

Loss of heterozygosity at pseudoautosomal regions in human breast cancer and association with negative hormonal phenotype.

Roncuzzi L, Brognara I, Cocchi S, Zoli W, Gasperi-Campani A.

Cancer Genet Cytogenet. 2002 Jun;135(2):173-6.

PMID:
12127402
6.

Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.

Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A.

Oncol Rep. 2005 Aug;14(2):471-4.

PMID:
16012732
7.

Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis.

Niederacher D, Picard F, van Roeyen C, An HX, Bender HG, Beckmann MW.

Genes Chromosomes Cancer. 1997 Mar;18(3):181-92.

PMID:
9071571
8.

ANX7, a candidate tumor suppressor gene for prostate cancer.

Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4575-80. Epub 2001 Apr 3.

10.

Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.

Utada Y, Haga S, Kajiwara T, Kasumi F, Sakamoto G, Nakamura Y, Emi M.

Cancer. 2000 Mar 15;88(6):1410-6.

PMID:
10717624
11.

Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer.

Nowacka-Zawisza M, Bryś M, Romanowicz-Makowska H, Kulig A, Krajewska WM.

Cancer Detect Prev. 2008;32(2):144-8. doi: 10.1016/j.cdp.2008.06.005. Epub 2008 Jul 16.

PMID:
18632222
12.

Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers.

Nagahata T, Hirano A, Utada Y, Tsuchiya S, Takahashi K, Tada T, Makita M, Kasumi F, Akiyama F, Sakamoto G, Nakamura Y, Emi M.

Breast Cancer. 2002;9(3):208-15.

PMID:
12185331
13.

Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer.

Beder LB, Gunduz M, Ouchida M, Gunduz E, Sakai A, Fukushima K, Nagatsuka H, Ito S, Honjo N, Nishizaki K, Shimizu K.

J Cancer Res Clin Oncol. 2006 Jan;132(1):19-27. Epub 2005 Sep 17.

PMID:
16170569
14.

Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.

Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, España P, Bonilla F.

Breast Cancer Res Treat. 1999 Oct;57(3):237-43.

PMID:
10617300
15.

Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.

Mustać E, Zamolo G, Petković M, Dordević G, Radić J, Grgurević E, Batinac T.

Coll Antropol. 2008 Sep;32(3):741-6.

PMID:
18982746
16.

Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor beta2 expression in breast carcinoma.

Yang Q, Yoshimura G, Nakamura M, Nakamura Y, Shan L, Suzuma T, Tamaki T, Umemura T, Mori I, Kakudo K.

Breast Cancer Res Treat. 2001 Nov;70(1):39-45.

PMID:
11767003
17.

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.

Schwarzenbach H, Müller V, Beeger C, Gottberg M, Stahmann N, Pantel K.

Breast Cancer Res. 2007;9(5):R66.

18.

Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer.

Caldés T, Perez-Segura P, Tosar A, de La Hoya M, Diaz-Rubio E.

Teratog Carcinog Mutagen. 2000;20(5):283-91.

PMID:
10992275
19.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

20.

Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.

Gabra H, Langdon SP, Watson JE, Hawkins RA, Cohen BB, Taylor L, Mackay J, Steel CM, Leonard RC, Smyth JF.

Clin Cancer Res. 1995 Sep;1(9):945-53.

Supplemental Content

Support Center